BR0213661A - Pré-concentrado de microemulsão e método para seu preparo, formulação farmacêutica e método para seu preparo, método para produzir imuno, supressão, método para aumentar os efeitos imuno supressores de isatx247, uso de formulação farmacêutica - Google Patents

Pré-concentrado de microemulsão e método para seu preparo, formulação farmacêutica e método para seu preparo, método para produzir imuno, supressão, método para aumentar os efeitos imuno supressores de isatx247, uso de formulação farmacêutica

Info

Publication number
BR0213661A
BR0213661A BR0213661-9A BR0213661A BR0213661A BR 0213661 A BR0213661 A BR 0213661A BR 0213661 A BR0213661 A BR 0213661A BR 0213661 A BR0213661 A BR 0213661A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical formulation
cyclosporine
isatx247
enhancing
Prior art date
Application number
BR0213661-9A
Other languages
English (en)
Inventor
Selvaraj Naicker
Randall W Yatscoff
Robert T Foster
Original Assignee
Isotechnika Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isotechnika Inc filed Critical Isotechnika Inc
Publication of BR0213661A publication Critical patent/BR0213661A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Abstract

"PRé-CONCENTRADO DE MICROEMULSãO E MéTODO PARA SEU PREPARO, FORMULAçãO FARMACêUTICA E MéTODO PARA SEU PREPARO, MéTODO PARA PRODUZIR IMUNO SUPRESSãO, MéTODO PARA AUMENTAR OS EFEITOS IMUNO SUPRESSORES DE ISA~ Tx~247, USO DE FORMULAçãO FARMACêUTICA". A presente invenção refere-se a formulações que contêm análogos de ciclosporina que são estruturalmente similares à ciclosporina A, particularmente misturas isoméricas de análogos de ciclosporina que são estruturalmente similares à ciclosporina A. As formulações formam pré-concentrados de microemulsão estáveis e podem propiciar uma biodisponibilidade superior da droga e/ou podem reduzir um ou mais efeitos adversos associados com a administração de ciclosporina. Também são apresentados métodos para usar e preparar as formulações.
BR0213661-9A 2001-10-19 2002-10-17 Pré-concentrado de microemulsão e método para seu preparo, formulação farmacêutica e método para seu preparo, método para produzir imuno, supressão, método para aumentar os efeitos imuno supressores de isatx247, uso de formulação farmacêutica BR0213661A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19
US37059702P 2002-04-05 2002-04-05
PCT/CA2002/001561 WO2003032949A1 (en) 2001-10-19 2002-10-17 Novel cyclosporin analog microemulsion preconcentrates

Publications (1)

Publication Number Publication Date
BR0213661A true BR0213661A (pt) 2004-10-26

Family

ID=26994747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213661-9A BR0213661A (pt) 2001-10-19 2002-10-17 Pré-concentrado de microemulsão e método para seu preparo, formulação farmacêutica e método para seu preparo, método para produzir imuno, supressão, método para aumentar os efeitos imuno supressores de isatx247, uso de formulação farmacêutica

Country Status (29)

Country Link
US (5) US7060672B2 (pt)
EP (2) EP2116228A1 (pt)
JP (3) JP2005506990A (pt)
KR (1) KR100978836B1 (pt)
CN (1) CN1274294C (pt)
AR (1) AR036852A1 (pt)
AT (1) ATE437629T1 (pt)
AU (1) AU2002333098B2 (pt)
BR (1) BR0213661A (pt)
CA (1) CA2461730C (pt)
CO (1) CO5580835A2 (pt)
DE (1) DE60233150D1 (pt)
DK (1) DK1435910T3 (pt)
ES (1) ES2330625T3 (pt)
HK (1) HK1062525A1 (pt)
HR (1) HRP20040354B1 (pt)
IL (3) IL160761A0 (pt)
MA (1) MA26221A1 (pt)
ME (1) MEP89008A (pt)
MX (1) MXPA04003623A (pt)
MY (1) MY145753A (pt)
NO (1) NO20042028L (pt)
NZ (1) NZ531946A (pt)
PL (1) PL206018B1 (pt)
PT (1) PT1435910E (pt)
RU (1) RU2317067C2 (pt)
TN (1) TNSN04070A1 (pt)
WO (1) WO2003032949A1 (pt)
ZA (1) ZA200402268B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1435910E (pt) * 2001-10-19 2009-09-07 Isotechnika Inc Novos pré-concentrados de microemulsão de análogos da ciclosporina
CA2518265A1 (en) * 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
JP2008514702A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
WO2006041631A2 (en) * 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
WO2008121096A1 (en) * 2005-05-19 2008-10-09 The Board Of Governors For Higher Education Monitoring cyclosporine in saliva
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
AU2007224006A1 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
WO2008055146A2 (en) * 2006-10-31 2008-05-08 Wyeth Formulations of phospholipase enzyme inhibitors
US20100113443A1 (en) * 2006-10-31 2010-05-06 Wyeth Liquid formulations of phospholipase enzyme inhibitors
JP5668476B2 (ja) * 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
CN107080734B (zh) 2008-03-20 2020-10-30 维尔恩公司 包含生育酚的peg衍生物的乳剂
EP2268274B1 (en) * 2008-03-20 2012-05-16 Virun, Inc. Vitamin e derivatives and their uses
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
CN102458370A (zh) 2009-06-09 2012-05-16 卢克斯生物科技公司 用于眼科用途的表面药物递送系统
KR20120104316A (ko) * 2009-12-10 2012-09-20 메르크 파텐트 게엠베하 올리고펩티드, 바람직하게는 실렌기티드를 포함하는 약학 조성물
CA2792330C (en) * 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
IT1404931B1 (it) * 2010-06-11 2013-12-09 Medivis S R L Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
US20110319467A1 (en) * 2010-06-23 2011-12-29 Bhiku Patel Absorption Enhancement of Statins and Omega Fatty Acids
MX338120B (es) * 2010-06-25 2016-04-04 Firmenich & Cie Sistema de suministro de ingredientes.
US9044394B2 (en) 2010-10-18 2015-06-02 PruGen IP Holdings, Inc. Bioavailability enhancement delivery composition
US20120095098A1 (en) * 2010-10-18 2012-04-19 Bhiku Patel Bioavailability Enhancement Delivery System
ES2705750T3 (es) 2010-12-15 2019-03-26 Contravir Pharmaceuticals Inc Moléculas análogas de la ciclosporina modificadas en los aminoácidos 1 y 3
WO2013090461A1 (en) * 2011-12-12 2013-06-20 PruGen IP Holdings, Inc. Statin bioavailability enhancement delivery composition
US8609684B2 (en) 2011-12-12 2013-12-17 PruGen IP Holdings, Inc. Solubilization and bioavailability of acetaminophen
EP2887923B1 (en) 2012-08-24 2023-04-05 Sun Pharmaceutical Industries Limited Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
CN106456556A (zh) * 2014-06-18 2017-02-22 豪夫迈·罗氏有限公司 包含非离子性表面活性剂的新型药物组合物
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
JP7072517B2 (ja) 2016-02-29 2022-05-20 サン ファーマ グローバル エフゼットイー 局所用シクロスポリン含有製剤およびその使用
EP3548896B1 (en) 2016-12-01 2021-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2019077123A1 (en) 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND KITS FOR IDENTIFYING WHETHER A SUBJECT IS REACHED OR RISK OF BEING WITH AUTOIMMUNE MYOPATHY
BR112021009967A2 (pt) * 2018-11-26 2021-08-17 Hepion Pharmaceuticals, Inc. formulações farmacêuticas de análogos de ciclosporina
WO2020115262A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
CA3126741A1 (en) 2019-01-15 2020-07-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
EP3981432A4 (en) 2019-03-27 2022-12-14 Tokyo Medical University THERAPEUTIC AGENT FOR WOLFRAM SYNDROME
KR102449537B1 (ko) * 2022-01-27 2022-10-05 주식회사 나노메디팜 근적외선을 이용하여 진단 생검 또는 종양 제거 수술 중에 종양 식별과 절제면 구분을 위한 종양 표적 진단 조영제

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH614931A5 (pt) * 1975-11-04 1979-12-28 Sandoz Ag
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
DE3260468D1 (en) * 1981-01-09 1984-09-06 Sandoz Ag Novel cyclosporins
CH667274A5 (de) * 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4764503A (en) * 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
NL194638C (nl) * 1986-12-19 2002-10-04 Novartis Ag Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
ES2059558T3 (es) * 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins y su uso como productos farmaceuticos.
EP0296123B1 (en) * 1987-06-19 1994-08-31 Sandoz Ag Cyclic peptolides
CA1326995C (en) * 1988-01-29 1994-02-15 Kozo Kurihara Cyclosporin compositions
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5284826A (en) * 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
DK0484281T4 (da) * 1990-11-02 2001-02-05 Novartis Ag Cyclosporiner
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
ATE139439T1 (de) * 1991-04-19 1996-07-15 Nexstar Pharmaceuticals Inc Pharmazeutische formulierung und pharmazeutisches verfahren
US5620971A (en) * 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US5248499A (en) * 1991-10-07 1993-09-28 Genentech, Inc. Control of microbial infections in transplant patients
US5759566A (en) * 1992-07-28 1998-06-02 Poli Industria Chimica Spa Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents
US5654000A (en) * 1992-07-28 1997-08-05 Poli Industria Chimica S.P.A. Pharmaceutical compositions for transmucosal delivery of peptides
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5639474A (en) * 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
ES2308955T5 (es) * 1993-09-28 2012-04-03 R.P. Scherer Gmbh Fabricación de cápsulas de gelatina blanda
US6022852A (en) * 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
DE69535127T2 (de) * 1994-03-18 2007-02-15 Supernus Pharmaceuticals, Inc. Emulgierte arzneistoffabgabesysteme
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
FI100692B (fi) * 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
JP2936209B2 (ja) * 1994-06-01 1999-08-23 ユーハン コーポレーション サイクロスポリン含有組成物およびその製造方法
CH686865A5 (de) * 1994-06-15 1996-07-31 Gergely Gerhard Pharmazeutische Zubereitung mit einem hydrophoben Wirkstoff und einem Brausesystem, sowie Verfahren zur Herstellung der Zubereitung.
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
US5603951A (en) * 1994-11-09 1997-02-18 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
WO1996033697A1 (fr) * 1995-04-24 1996-10-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulation auto-emulsionnable formant une emulsion huile dans l'eau
US5656287A (en) * 1995-06-07 1997-08-12 Nexstar Pharmaceuticals, Inc. Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications
US5693336A (en) * 1995-06-07 1997-12-02 Nexstar Pharmaceuticals, Inc. Blood stable liposomal cyclosporin formulations
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
AU709548B2 (en) * 1995-08-25 1999-09-02 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
NZ280689A (en) * 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
US5660858A (en) * 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
KR980008239A (ko) * 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
DE69714861T2 (de) * 1996-07-30 2003-05-22 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky
CZ267796A3 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
CA2185600A1 (en) 1996-09-16 1998-03-17 Bernard Charles Sherman Water-soluble concentrates containing cyclosporins
US5798333A (en) * 1996-09-17 1998-08-25 Sherman; Bernard C. Water-soluble concentrates containing cyclosporins
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
CZ301382B6 (cs) * 1997-03-12 2010-02-10 Abbott Laboratories Chad377/Ap6D-2 Hydrofilní binární systémy pro podávání cyklosporinu
CA2285983A1 (en) * 1997-04-29 1998-11-05 Bernard Charles Sherman Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride
NZ314702A (en) * 1997-04-29 1998-07-28 Bernard Charles Sherman Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
IN188719B (pt) * 1997-09-08 2002-11-02 Panacea Biotec Ltd
US6346511B1 (en) * 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6187747B1 (en) * 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
KR100551221B1 (ko) * 1997-09-09 2006-02-10 리오트로픽테라피우틱스 인코퍼레이션 코팅된 입자, 그 제조방법 및 그 사용방법
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
AU1508899A (en) * 1997-12-02 1999-06-16 Chong Kun Dang Corporation Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US6028067A (en) * 1997-12-05 2000-02-22 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
ES2241663T3 (es) * 1999-09-21 2005-11-01 Skyepharma Canada Inc. Composiciones particuladas modificadas superficialmente de substancias biologicamente activas.
AU7638200A (en) * 1999-10-20 2001-04-30 Vesifact Ag Microemulsion preconcentrates which contain cyclosporines and corresponding microemulsions
PT1435910E (pt) * 2001-10-19 2009-09-07 Isotechnika Inc Novos pré-concentrados de microemulsão de análogos da ciclosporina

Also Published As

Publication number Publication date
RU2004110936A (ru) 2005-05-27
MA26221A1 (fr) 2004-07-01
NZ531946A (en) 2005-09-30
US7429562B2 (en) 2008-09-30
RU2317067C2 (ru) 2008-02-20
CA2461730C (en) 2012-05-15
EP1435910A1 (en) 2004-07-14
US7829533B2 (en) 2010-11-09
HK1062525A1 (en) 2004-11-12
EP1435910B1 (en) 2009-07-29
US20110136744A1 (en) 2011-06-09
WO2003032949A1 (en) 2003-04-24
ZA200402268B (en) 2005-05-25
DK1435910T3 (da) 2009-11-09
AU2002333098B2 (en) 2006-03-16
CN1274294C (zh) 2006-09-13
HRP20040354A2 (en) 2005-02-28
ES2330625T3 (es) 2009-12-14
IL160761A0 (en) 2004-08-31
ATE437629T1 (de) 2009-08-15
DE60233150D1 (de) 2009-09-10
CA2461730A1 (en) 2003-04-24
IL160761A (en) 2010-11-30
PL370560A1 (en) 2005-05-30
US7060672B2 (en) 2006-06-13
US20140249092A1 (en) 2014-09-04
MY145753A (en) 2012-03-30
MEP89008A (en) 2011-12-20
EP1435910B9 (en) 2010-02-03
US20060217309A1 (en) 2006-09-28
KR100978836B1 (ko) 2010-08-30
TNSN04070A1 (en) 2006-06-01
JP2005506990A (ja) 2005-03-10
US20090054311A1 (en) 2009-02-26
AR036852A1 (es) 2004-10-06
NO20042028L (no) 2004-05-14
EP2116228A1 (en) 2009-11-11
US20030171264A1 (en) 2003-09-11
PT1435910E (pt) 2009-09-07
JP2012158609A (ja) 2012-08-23
CN1571657A (zh) 2005-01-26
JP2009073850A (ja) 2009-04-09
IL195892A (en) 2013-09-30
HRP20040354B1 (en) 2012-10-31
KR20050037418A (ko) 2005-04-21
CO5580835A2 (es) 2005-11-30
MXPA04003623A (es) 2004-12-02
PL206018B1 (pl) 2010-06-30

Similar Documents

Publication Publication Date Title
BR0213661A (pt) Pré-concentrado de microemulsão e método para seu preparo, formulação farmacêutica e método para seu preparo, método para produzir imuno, supressão, método para aumentar os efeitos imuno supressores de isatx247, uso de formulação farmacêutica
YU73503A (sh) Preparati insulina koji ne sadrže cink ili sadrže male količine cinka i koji imaju poboljšanu stabilnost
ECSP045060A (es) Nuevas formulaciones analogas de ciclosporina
HUP0300836A2 (hu) Taxánokat tartalmazó szájon át beadható gyógyszerkészítmények és ezek alkalmazása
RS105704A (sr) Kiseli preparati insulina sa poboljšanom stabilnošću
UY23864A1 (es) Procedimiento para preparar nuevas composiciones farmaceuticas a base de ciclosporinas
WO2002051390A3 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
WO2000056361A3 (en) Vaccine composition
HK1088840A1 (en) Stable analogs of glp-1 glp-1
DE69309078D1 (de) N-methylierte zyklische undecapeptide enthaltende arzneimittelzubereitungen
WO2002080965A3 (en) Vaccine composition
HUP0500843A2 (hu) Fokozott biológiai hasznosulású, szájon át hatásos taxánszármazékokat tartalmazó gyógyszerkészítmények
HUP0302857A2 (hu) Gyógyszerészeti kiszerelés
DE60138222D1 (de) Modulierung von il-2 und il-15 vermittelten t zellantworten
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
BRPI0414721A (pt) formulações estabilizadas de fosfatidilserina
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
ES2140837T3 (es) Adyuvante a base de saponina de madera de panama y formulacion de vacuna que lo contiene.
WO1996009805A3 (en) Chitosan induced immunopotentiation
AR117150A1 (es) Formulaciones farmacéuticas de análogos de ciclosporina
HUP0400115A2 (hu) Gyógyászati készítmény fulvesztrant intramuszkuláris beadására
BR9807406A (pt) Formulação farmacêutica, e, processo para a preparação das mesmas
AR040242A1 (es) Composiciones farmaceuticas
YU32904A (sh) Novi analog ciklosporina za formiranje mikroemulzionih prekoncentrata
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 9/107, 38/13; A61P 29/00, 37/06, 37/00

Ipc: A61K 9/107 (2011.01), A61K 38/13 (2011.01), A61P 2

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2328 DE 18-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.